	US 12,259,388 B2
	Cofilin phosphorylation for quantifying CD4 T cell damage and predict CD4 T cell recovery from anti-retroviral therapy
Yuntao Wu, Manassas, VA (US); Hong Shang, Manassas, VA (US); and Yajing Fu, Manassas, VA (US)
Assigned to VIRONGY L.L.C., Manassas, VA (US)
Appl. No. 16/963,908
Filed by VIRONGY L.L.C., Manassas, VA (US)
PCT Filed Jan. 23, 2019, PCT No. PCT/US2019/014756 § 371(c)(1), (2) Date Jul. 22, 2020, PCT Pub. No. WO2019/147678, PCT Pub. Date Aug. 1, 2019.
Claims priority of provisional application 62/620,598, filed on Jan. 23, 2018.
Prior Publication US 2021/0041437 A1, Feb. 11, 2021
Int. Cl. A61P 31/18 (2006.01); A61K 31/35 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01)

CPC G01N 33/56972 (2013.01) [A61K 31/35 (2013.01); A61P 31/18 (2018.01); G01N 33/57496 (2013.01); G01N 2333/16 (2013.01); G01N 2333/4712 (2013.01); G01N 2440/14 (2013.01)]

2 Claims

1. A method for treating cancer in a patient, comprising

(a) quantifying cofilin phosphorylation levels in one or more cells chosen from helper CD4+ T cells, cytotoxic CD8+ T cells, B cells, and/or natural killer cells, of said patient, wherein said patient has lower or higher cofilin phosphorylation levels than a control healthy person; and

(b) administering to said patient an effective amount of a composition that restores cofilin phosphorylation.